Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma

This study is currently recruiting participants.

Verified by Katholieke Universiteit Leuven, March 2008

First Received: July 2, 2007 Last Updated: November 25, 2008 History of Changes

Sponsors and Collaborators:	Katholieke Universiteit Leuven Fund for Scientific Research, Flanders, Belgium IWT, Flanders, Belgium
Information provided by:	Katholieke Universiteit Leuven
ClinicalTrials.gov Identifier:	NCT00495924

Purpose

The purpose of this study is to determine whether early recurrence after curative resection of ductal pancreatic adenocarcinoma can be explained by either dissemination of cancer cells during intraoperative tumour manipulation, post-operative systemic immune suppression, alteration of biological properties of circulating cancer cells or a combination of these.

Condition	Intervention
Pancreatic Neoplasms Adenocarcinoma Neoplasm Circulating Cells Tumor Markers, Biological Monitoring, Immunologic	Procedure: Pancreatic resection (PD)

Study Type:	Observational
Study Design:	Prospective
Official Title:	Prognostic Relevance of Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma

Resource links provided by NLM:

MedlinePlus related topics: Cancer Pancreatic Cancer

U.S. FDA Resources

Further study details as provided by Katholieke Universiteit Leuven:

Estimated Enrollment:	100
Study Start Date:	October 2006
Estimated Study Completion Date:	October 2008

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Suspected ductal pancreatic adenocarcinoma (pathological confirmation required after resection of tumour);
Informed consent.

Exclusion Criteria:

Any malignant tumour within 5 years prior to pancreatic resection.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00495924

Contacts

Contact: Baki Topal, MD, PhD	0032(0)16343149	baki.topal@uz.kuleuven.ac.be
Contact: Gregory Sergeant, MD	0032(0)1644377	gregory.sergeant@uz.kuleuven.ac.be

Locations

Belgium, Vlaams-Brabant
Department of Abdominal Surgery, Catholic University Leuven	Recruiting
Leuven, Vlaams-Brabant, Belgium, B-3060
Contact: Baki Topal, MD, PhD 0032(0)16343149 baki.topal@uz.kuleuven.ac.be
Contact: Gregory Sergeant, MD 0032(0)16344377 gregory.sergeant@uz.kuleuven.ac.be

Sponsors and Collaborators

Katholieke Universiteit Leuven

Fund for Scientific Research, Flanders, Belgium

IWT, Flanders, Belgium

Investigators

Study Director:	Baki Topal, MD, PhD	Catholic University Leuven, Belgium
Principal Investigator:	Gregory Sergeant, MD	Catholic University Leuven

More Information

Additional Information:

Official site of the Department of Abdominal Surgery, Catholic University Leuven This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	3M070038, G.0635.07
Study First Received:	July 2, 2007
Last Updated:	November 25, 2008
ClinicalTrials.gov Identifier:	NCT00495924 History of Changes
Health Authority:	Belgium: Ministry of Social Affairs, Public Health and the Environment

Study placed in the following topic categories:

Digestive System Neoplasms
Pancreatic Neoplasms
Endocrine System Diseases
Carcinoma
Digestive System Diseases
Neoplasm Metastasis
Gastrointestinal Neoplasms

Pancreatic Diseases
Endocrinopathy
Adenocarcinoma
Neoplasm Circulating Cells
Neoplasms, Glandular and Epithelial
Endocrine Gland Neoplasms

Additional relevant MeSH terms:

Neoplasms by Histologic Type
Digestive System Neoplasms
Pancreatic Neoplasms
Endocrine System Diseases
Carcinoma
Neoplasms
Neoplastic Processes
Digestive System Diseases

Pathologic Processes
Neoplasms by Site
Neoplasm Metastasis
Pancreatic Diseases
Adenocarcinoma
Neoplasm Circulating Cells
Neoplasms, Glandular and Epithelial
Endocrine Gland Neoplasms

ClinicalTrials.gov processed this record on July 02, 2009